ATE494909T1 - Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung - Google Patents

Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung

Info

Publication number
ATE494909T1
ATE494909T1 AT03811387T AT03811387T ATE494909T1 AT E494909 T1 ATE494909 T1 AT E494909T1 AT 03811387 T AT03811387 T AT 03811387T AT 03811387 T AT03811387 T AT 03811387T AT E494909 T1 ATE494909 T1 AT E494909T1
Authority
AT
Austria
Prior art keywords
antigen complexes
vaccination
production
compositions containing
antigens
Prior art date
Application number
AT03811387T
Other languages
English (en)
Inventor
Antonius Stegmann
Original Assignee
Bestewil Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bestewil Holding Bv filed Critical Bestewil Holding Bv
Application granted granted Critical
Publication of ATE494909T1 publication Critical patent/ATE494909T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT03811387T 2002-11-20 2003-11-20 Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung ATE494909T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02102610 2002-11-20
EP0350638 2003-09-18
PCT/EP2003/013084 WO2004045641A2 (en) 2002-11-20 2003-11-20 Antigen-complexes

Publications (1)

Publication Number Publication Date
ATE494909T1 true ATE494909T1 (de) 2011-01-15

Family

ID=34379291

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03811387T ATE494909T1 (de) 2002-11-20 2003-11-20 Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung

Country Status (5)

Country Link
EP (1) EP1578443B1 (de)
AT (1) ATE494909T1 (de)
AU (1) AU2003296592A1 (de)
DE (1) DE60335742D1 (de)
WO (1) WO2004045641A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
TWI329130B (en) * 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
EP2549990A1 (de) * 2010-03-23 2013-01-30 Irm Llc Verbindungen (cysteinbasierte lipopeptide) und zusammensetzungen als tlr2-agonisten zur behandlung von infektionen, entzündungen, atemwegserkrankungen etc.
DK3728287T3 (da) * 2017-12-19 2024-06-10 CSL Behring Lengnau AG Proteinoprensning og virusinaktivering med alkylglycosider
CN117147882B (zh) * 2023-10-31 2024-01-26 中国农业科学院生物技术研究所 抗虫蛋白Cry 1Ah酶联免疫定量检测试剂盒及方法
CN119552272A (zh) * 2025-01-21 2025-03-04 北京华诺泰生物医药科技有限公司 一种水痘-带状疱疹病毒gE融合蛋白、制备方法及其应用
CN119925588B (zh) * 2025-04-08 2025-07-01 北京华诺泰生物医药科技有限公司 基于gE/pORF7双抗原纳米晶与智能相变佐剂的重组带状疱疹疫苗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
EP0231039B1 (de) * 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Verfahren zur Herstellung immunologischer Komplexe und diese enthaltende pharmazeutische Zusammensetzung
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
CA2086831C (en) 1991-05-08 1999-03-16 Reinhard Gluck Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
FR2771640B1 (fr) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
US6733985B1 (en) * 1999-05-19 2004-05-11 International Technidyne Corporation Preparation of stable liquid and dried synthetic prothrombin time reagents
WO2001060402A2 (en) * 2000-02-15 2001-08-23 Intellivax International Inc. Proteosome influenza vaccine
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions

Also Published As

Publication number Publication date
WO2004045641A3 (en) 2005-02-03
EP1578443B1 (de) 2011-01-12
WO2004045641A2 (en) 2004-06-03
AU2003296592A8 (en) 2004-06-15
AU2003296592A1 (en) 2004-06-15
DE60335742D1 (de) 2011-02-24
EP1578443A2 (de) 2005-09-28

Similar Documents

Publication Publication Date Title
Bergmann-Leitner et al. Adjuvants in the driver’s seat: how magnitude, type, fine specificity and longevity of immune responses are driven by distinct classes of immune potentiators
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
RU2009144125A (ru) Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе
EP1917033A4 (de) Virusähnliche partikel als paramyxovirus-impfstoffe
IL150602A0 (en) Proteosome influenza vaccine
EP1584685A3 (de) Tumorassoziierte Antigenderivate der Mage-Familie, Nukleinsäuresequenzen, die dafür kodieren, zur Herstellung von Fusionsproteinen und Zusammensetzungen zur Impfung
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
DE60117164D1 (de) Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
WO2005037190A3 (en) Multiplex vaccines
WO2004098533A3 (en) Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
EP2368576A3 (de) Funktionell neu errichtete Virenmembranen mit Adjuvantien
DE602005025342D1 (de) Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
WO2004026265A3 (en) Compositions and methods for treatment of herpesvirus infections
WO2005007673A3 (en) Immunogenic peptides
NO20090177L (no) Vaksiner for malaria
Martelet et al. Porcine dendritic cells as an in vitro model to assess the immunological behaviour of Streptococcus suis subunit vaccine formulations and the polarizing effect of adjuvants
WO2008118487A3 (en) Compositions and methods for incresing immunogenicity of glycoprotein vaccines
ATE494909T1 (de) Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung
JP7016317B2 (ja) アジュバント組成物
WO2024047091A3 (en) Veterinary compositions of modified virus-like particles of cmv and ngf antigens
WO2002053588A3 (en) Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of chlamydia psittaci
ATE500848T1 (de) Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerprotein
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
WO2002036160A3 (es) Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica
Kahraman et al. A novel trivalent inactivated Salmonella vaccine formulated with CpG ODNs to enhance the cellular immunity in chickens

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1578443

Country of ref document: EP